The breadth and dollar magnitude of this insider cluster — spanning the President, CFO/CLO, Chief Commercial Officer, Chief Early Development, CTO, and two directors — with zero insider purchases and no 10b5-1 plans, suggests coordinated awareness of near-term headwinds. Watch for upcoming clinical data readouts, regulatory updates, or financing needs that could explain the urgency. The stock's recent run to ~$37 may have provided a window for insiders to lock in gains.
Price Chart
Executive Summary
Eight Pharvaris insiders sold a total of $7.35M in open-market sales over a one-week window, including the President ($3.5M), a Director ($1.99M), and the CFO/CLO ($219K). The cluster is dominated by senior management and board members, with no offsetting purchases. This represents approximately 2.3% of the company's $326M market cap, exceeding the 2% materiality threshold. The sales are not plan-driven (no 10b5-1 indication) and are concentrated among top executives, making this a bearish signal of informed selling ahead of potential negative catalysts.
Key Financial Metrics
Key Facts
- 8 insiders sold shares totaling $7.35M in open-market transactions over 7 days
- President Lu Peng sold $3.5M (100K shares at $35.00) — the largest single trade
- Director Bjork Elisabeth sold $1.99M (52.5K shares at $37.89)
- CFO/CLO Nassif David W. sold $219K (6K shares at $36.47) plus a $0 gift of 500 shares
- Total sales represent ~2.3% of PHVS's $326M market cap — highly material
- No insider purchases were reported in the cluster window
- No 10b5-1 trading plan indicated for any of the sales
- C-suite (President, CFO/CLO, CCO, Chief Early Dev, CTO) participated alongside directors
Financial Impact
Insider sales of $7.35M represent ~2.3% of market cap, concentrated among top executives with no purchases. This is a strong bearish signal per the insider-selling literature.
Risk Factors
- Potential negative clinical trial results or regulatory setback for Pharvaris's HAE pipeline
- Possible dilutive financing or secondary offering on the horizon
- Insider sales may signal deteriorating confidence in near-term commercial prospects
- Stock could face selling pressure as market digests the magnitude of insider exits
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-PHVS-1790318284493 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 25, 2026 4w ago | Insider Cluster | $32.02 $31.19 | ▲ +2.59% | ▲ +2.37% | $31.95 (+0.22%) |
Sep 24, 2026 4w ago | Insider Cluster | $32.99 $31.01 | ▲ +6.00% | ▲ +5.59% | $31.95 (+3.15%) |
Sep 24, 2026 4w ago | Insider Cluster | $32.99 $31.01 | ▲ +6.00% | ▲ +5.59% | $31.95 (+3.15%) |
Sep 23, 2026 4w ago | Insider Cluster | $33.07 $31.72 | ▲ +4.08% | ▲ +3.41% | $31.95 (+3.39%) |
Sep 21, 2026 5w ago | Insider Cluster | $36.02 $31.91 | ▲ +11.41% | ▲ +10.39% | $31.95 (+11.30%) |
Sep 17, 2026 5w ago | 144 | $36.37 $32.02 | ▲ +11.96% | ▲ +13.23% | $31.95 (+12.15%) |
Sep 17, 2026 5w ago | Insider Cluster | $38.00 $32.99 | ▲ +13.18% | ▲ +13.78% | $31.95 (+15.92%) |
Sep 17, 2026 5w ago | Insider Cluster | $38.00 $32.99 | ▲ +13.18% | ▲ +13.78% | $31.95 (+15.92%) |
Sep 16, 2026 5w ago | Insider Cluster | $37.55 $33.07 | ▲ +11.93% | ▲ +13.76% | $31.95 (+14.91%) |
Sep 15, 2026 6w ago | Insider Cluster | $38.06 $36.37 | ▲ +4.44% | ▲ +5.26% | $31.95 (+16.05%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers